G
GnuBIO
Developer of scalable dna sequencing technology for the diagnostic and applied markets
About GnuBIO
GnuBIO operates in the biotechnology sector, specializing in next-generation DNA sequencing technology. The company has developed an innovative desktop sequencer that integrates all the functions of DNA sequencing into a single, low-cost instrument. Unlike traditional sequencing technologies that require separate workflows for target selection, DNA amplification, sequencing, and analysis, GnuBIO's platform consolidates these steps into one streamlined process. This results in faster genomic results, reducing the time from days to mere hours.
GnuBIO primarily serves research institutions, clinical laboratories, and pharmaceutical companies that require efficient and accurate genomic data for various applications, including medical research, diagnostics, and drug development. The company's business model revolves around the sale of its proprietary sequencing instruments and related consumables, generating recurring revenue from the continuous use of its platform.
The market GnuBIO operates in is highly competitive, with a growing demand for faster and more cost-effective genomic sequencing solutions. The company's unique value proposition lies in its ability to deliver integrated sequencing with a single user interface, making the process more accessible and less time-consuming for its clients.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2009
- Headquarters
- Cambridge, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 59.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Apr 2014 | $50M | $50M | Bio-Rad Laboratories | — |
| SERIES B✓Equity / VC | Oct 2012 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for GnuBIO is 330 monthly website visits, down 15.4% over the last three months. GnuBIO's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
Bio-Rad Laboratories
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about GnuBIO on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GnuBIO’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







